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Summary 
Vaccines  designed  to  protect against  malaria  by inducing  CD8 +  cytotoxic T  lymphocytes 
(CTL) in individuals of diverse HLA backgrounds must contain multiple conserved epitopes 
from various preerythrocytic-stage antigens. Plasmodiumfalciparum sporozoite surface protein 2 
(PfSSP2)  is  considered an important antigen for inclusion in  such vaccines, because  CD8 + 
CTL against the P. yoelii SSP2 protect mice against malaria by eliminating infected hepatocytes. 
To develop PfSSP2 as a component of malaria vaccines, we investigated the presence of anti- 
PfSSP2 CTL in two HLA-B8  + volunteers immunized with irradiated P. falciparum  sporozoites 
and characterized their CTL responses using PfSSP2-derived 15-amino acid peptides bearing 
the HLA-B8-binding motif. Peripheral blood mononuclear cells from both volunteers stimu- 
lated with recombinant vaccinia expressing PfSSP2 displayed antigen-specific, genetically re- 
stricted, CD8 + T  cell-dependent CTL activity against autologous target cells expressing PfSSP2. 
Of the five HLA-B8 motif-bearing 15-mers identified in the PfSSP2 sequence, two peptides 
sharing a 10-amino acid overlap sensitized HLA-B8-matched target cells from both volunteers 
for lysis by peptide-stimulated effectors. The CTL activity was HLA-B8 restricted and depen- 
dent on CD8 + T cells. Analysis of the three shorter peptides representing HLA-B8 motif-bear- 
ing sequences within the two positive peptides for their ability to bind to HLA-B8 in vitro, and 
to sensitize target cells for lysis by effectors stimulated with the  15-mers, identified two over- 
lapping HLA-BS-restricted CTL epitopes. Available data indicate that  the sequence of one 
CTL epitope is conserved and the other is variant among P. falciparum  isolates.  Circulating acti- 
vated CTL against  the conserved epitope could be directly identified in one of the two volun- 
teers.  The identification of two HLA-B8-restricted CTL epitopes on PfSSP2 provides data 
critical to developing an epitope-based anti-liver stage malaria vaccine. 
T 
here are an estimated 300-500 million clinical cases of 
malaria, and 1-2 million deaths are caused by malaria 
each year (1).  One approach to malaria vaccine develop- 
ment is to induce CD8 § CTL that recognize parasite-derived 
peptides  complexed with  class I  MHC  molecules on the 
surface  of Plasmodium  sp.-infected  hepatocytes  (2).  This 
work is primarily based on the observations that immuniza- 
tion of mice (3), monkeys (4), and humans (5-10) with the 
respective  Plasmodium  sp.-irradiated  sporozoites  (irr  spz) 1 
protects  against  malaria,  that  this  immunity  is  directed 
against  infected hepatocytes (11),  and that such protection 
1Abbreviations used in this paper: [32m  , [32-microglobulin;  B-LCL, lympho- 
bhstoid B cell lines; irr spz, irradiated sporozoites; OM, opti-MEM I; 
PfSSP2, P. falciparum SSP2; SSP2, sporozoite  surface  protein 2, TCM, T 
cell medium. 
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CD8 + T  cells (12,  13). 
Two  preerythrocytic-stage  Plasmodium  sp.  proteins,  the 
circumsporozoite protein  (14)  and sporozoite surface pro- 
tein  2  (SSP2)  (15),  also known as TRAP  (16),  have been 
definitively identified as targets of this CD8 + T  cell-depen- 
dent protection,  because CD8 + T  cell clones against both 
proteins  adoptively transfer protection  against  rodent  ma- 
larias  (17-20).  It is our view that optimal development  of 
human malaria vaccines designed to induce protective CTL 
will  require  identification  of CTL  epitopes  on  these  and 
other preerythrocytic-stage antigens,  and definition  of the 
class  I  HLA  molecules  restricting  such  determinants.  A 
peptide representing P. falciparum circumsporozoite protein 
residues 368-390 shown first to include an H-2~restricted 
CD8 + CTL epitope (21) was later shown to contain CD8 + 
CTL epitopes  recognized by humans  immunized with  irr 
spz (22) and naturally exposed to malaria (23-25). Thus far, 
only  an  HLA-B35-restricted  nonamer  epitope  has  been 
identified  within  this  peptide  (25).  We  recently  reported 
the presence ofCTL epitopes on P.falciparum  SSP2 (PfSSP2) 
in mice (26), and we have undertaken a systematic investi- 
gation to identify PfSSP2 CTL epitopes restricted by a va- 
riety of class I HLA alleles. 
Naturally processed peptides bound to class I MHC mol- 
ecules  have  restricted  lengths  (usually  8-10  residues)  and 
bear  crucial  residues  at  defined  positions.  These  features 
have led to the identification of allele-specific binding mo- 
tifs  (27)  and  have  allowed  for  the  rapid  identification  of 
CTL epitopes within proteins  of interest  (25,  28,  29). We 
now report the identification through use of the HLA-B8- 
binding motif (30-32)  of two minimal  overlapping HLA- 
B8-restricted CTL epitopes on PfSSP2. 
Materials and Methods 
Human  Volunteers and Immunization.  Two HLA-B8  + individ- 
uals, volunteers 16 and 17, were immunized with P. fakiparum irr 
spz as previously described  (9) (Table  1). Briefly,  after giving in- 
formed consent to a protocol approved by an institutional  review 
board, the volunteers were immunized by exposure to the bites of 
irradiated  (1.5 ￿  104 rad) Anopheles stephensi mosquitoes  infected 
with  either the NF54 strain  (33) or 3D7  clone  (34) of P. falci- 
parum. Over a period of 23 too, volunteers  16 and 17 were ex- 
posed to 1,415  and 1,398  infectious  bites,  in 11 and 10 sessions, 
respectively  (Table  1). 
Synthetic Peptides.  A panel of 113 synthetic 15-mers overlap- 
ping by 10  residues  and spanning the entire  PfSSP2 (3D7)  se- 
quence (15) was synthesized by the solid-phase  "tea-bag" method 
(35). For these  studies,  five peptides  were selected  based  on the 
presence of the HLA-B8-binding motif (30-32) (Table 2). HLA- 
B8 motif-bearing sequences within selected 15-mers contain eight 
to nine  amino acid segments  with  a Lys  (K)  or an Arg (R)  as 
dominant anchor residues at positions  3 (P3) and 5 (P5), and Leu 
(L), Ile (I), or the hydrophobic residue Val (V) as auxiliary anchor 
residues  at positions  8 or 9 (COOH terminus).  Six shorter pep- 
tides corresponding to HLA-B8 motif-bearing sequences  (Table 
2)  were  synthesized  using solid-phase  Fmoc chemistry.  PfSSP2 
peptide  99  (residues 491-505;  REEHEKPDNNKKKAG),  the 
HLA-B8-restricted influenza  type A  nucleoprotein peptide  NP 
380-388  (ELRSRYWAI)  (30,  32),  the  HLA-A2.1-restricted 
hepatitis B core peptide HBcAg 18-27 (FLPSDYFPSV)  (36), and 
the  breakpoint  region  protein  peptide  BCR  1303-1311  (LTI- 
NKEDDE) (37) were used as control peptides.  Purity of peptides 
was assessed by reverse-phase  HPLC, and the structure of shorter 
peptides  was verified  by mass spectrometric analysis. Lyophilized 
peptides  were  dissolved  in  DMSO,  and  stock  solutions  were 
stored at  -20~  Before use, peptides  were diluted with RPMI 
1640. Peptides  were not toxic to cell cultures or target cells. 
HLA-B8-binding Assay.  rHLA-B8 H  chains  (residues 1-278) 
were prepared from Escherichia coli inclusion  bodies  as described 
(31, 38).  HLA complexes were reconstituted with 25 ~g of iso- 
lated  rHLA-B8 H  chains  dissolved  in 2.5  pA of 8.8 M  urea/25 
mM 4-morpholineethanesulfonic acid/150 mM NaC1,  pH 6.5, 
1  ~1 of peptide  dissolved  in DMSO  (10 mg/ml),  and 5  ￿  103 
cpm of 12SI-labeled human [32-microglobulin  ([~2m) (sp act 1 ￿ 
1017-1  ￿  10  TM  cpm/mol) in a final volume of 50 pA. Reconsti- 
tuted HLA complexes were separated  from unincorporated [~2  m 
by HPLC gel f11tration. Peptide binding was measured indirectly 
Table 1,  HLA Phenotypes of Volunteers Immunized by the Bites of Irradiated Anopheles Mosquitoes Infected with P. falciparum (NF54 
or 3D7) and of Control Target Cells 
HLA type  Immunizing  Infectious 
Cells  (class I)  doses*  bitesr 
Volunteers 
16 
17 
Controls 
WR 
RH 
GR 
A1, A24, B8, B38, Bw4, Bw6, Cw7 
A1, A3, B7, B8, Bw6 
A1, A28, B44, Bw57, Cw6 
A2, B62, B65, Bw6, Cw3, Cw8 
A24, A28, B7, B14, Cw7, Cw8 
11  1415 
I0  1398 
Over a 23-mo period: 
* Total number of exposures to the bites of  irradiated infected mosquitoes. 
*Total number of infectious bites from irradiated infected mosquitoes. 
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Peptide  Sequence*  Residues* 
15-mers 
7 
21 
22 
52 
53 
8- or 9-mers 
7.1 
22.1 
22.2 
22.3 
52.1 
52.2 
NIVDEIKYI~EEVCND 
IRLHSDASKNKEKAL 
DASKNKEKALIIIKS 
TCGKGTRSRKREILH 
TRSRKREILHEGCTS 
31-45 
101-115 
106-120 
256-270 
261-275 
EIKYREEV  35-42 
ASKNKEKAL  107-115 
KNKEKALII  109-117 
KNKEKALI  109-116 
GTRSRKREI  260-268 
ILSRKREIL  262-269 
*Sequence in single-letter amino acid code. Binding motif for HLA- 
B8: K/R at position 3 and K/R. at position 5 (primary anchor residues); 
L/I/hydrophobic  at position 8 or 9 (auxiliary  anchor residues) (30-32). 
Primary and auxiliary  anchor residues are in bold; polymorphic residues 
(53) are underlined. 
:~Numbering  system refers to the PfSSP2 (3D7) sequence. 
by monitoring their ability to promote the incorporation of 1251- 
~2m into HLA H  chain-132m-peptide  heterotrimeric complexes. 
To determine the stability of such complexes,  the tl/2 rate of dis- 
sociation ofpeptides from HLA complexes was measured at 37~ 
as previously described  (39). 
Construction of Recombinant Vaccinia Virus Expressing PfSSP2. 
The generation of a recombinant  vaccinia virus, vP 1155, express- 
ing full-length PfSSP2 (3D7) has been previously described (26). 
Plasmid Construction.  The PfSSP2  (3D7)  genomic DNA se- 
quence was excised  from plasmid pPfSSP2.43  (15) by digestion 
with SacI/Klenow and BamHI. The insert was then cloned into 
the expression  vector pH[3APr-l-neo (40) (pHbAn), which had 
been digested  with HindllI/Klenow and BamHI. The resulting 
plasmid pHbAnSSP2 was used for transfection of target cells. 
Cell Lines.  All EBV-transformed lymphoblastoid B cell lines 
(B-LCL), with the exception of GiL cells (kindly provided by Dr. 
B. D. Walker, Massachusetts General Hospital/Harvard Medical 
School, Boston, MA), were estabhshed from freshly isolated PBMC 
using culture supematant of the B95.8  marmoset cell line (41) 
(Table 1). Hmy2.CIIL cells (42) transfected with HLA-B8 cDNA 
(HLA-B8-Hmy2.CIR) (31) (kindly supplied by Dr. W. E. Bidd- 
ison, National Institutes of Health, Bethesda, MD) and all B-LCL 
were  maintained in  RPMI  1640  supplemented with  10  mM 
Hepes,  2 mM t-glutamine, 0.1 mM nonessential amino acids, 50 
U/ml penicillin, 50  ~zg/ml streptomycin (GIBCO BILL, Gaith- 
ersburg,  MD), and 10% heat-inactivated FCS (JILH Biosciences, 
Lenexa, KS) (CIL). Opti-MEM I (GIBCO BILL) (OM) was used 
for transient transfection of target cells. 
In Vitro Stimulation of PBMC.  2-4 wk after the last exposure 
to irradiated infected mosquitoes, PBMC were isolated from hep- 
arinized venous blood or from leukophoresis  runs by density gra- 
dients over lymphocyte separation  medium (Organon Teknika, 
Durham, NC). PBMC (3 ￿  106 cells/well)  were cultured in 24- 
well plates in a final volume of 2 ml ILPMI 1640 prepared as for 
CR but substituting heat-inactivated pooled normal AB + human 
serum for FCS (T cell medium [TCM]). For vaccinia stimulation, 
one-third of the PBMC in culture were infected with vP 1155 (10 
PFU/cell, 5  X  106  cells/ml in RPMI  1640,  1 h  at 37~  5% 
CO2). For peptide stimulation, PBMC were cultured in the pres- 
ence of individual peptides  (15 IxM), and, 2 d after initiation of 
the culture, rhlL-2 (Cetus  Corp., Emeryville,  CA) was added to 
each well (50 U/ml). Plates were incubated for 6 d at 37~  5% 
CO  2.  Unstimulated PBMC  that  did not undergo secondary  in 
vitro stimulation were also tested as effector cells. 
Target Ceils.  B-LCL were transiently transfected  48 h before 
use as targets in the SlCr-release assay. In a final volume of 100 Ixl, 
10 ixg ofpHbAnSSP2 or pHbAn DNA was mixed with 30 Ixg of 
Lipofectin reagent (1:1  [wt/vt]  liposome formulation of N-[1- 
(2,3-dioleyloxy)  propyl]-N, N,  N-trimethylammonium chloride 
and dioleyl phosphotidylethanolamine) (GIBCO BILL), and the 
mixture was incubated for 20 min at room temperature. DNA- 
Lipofectin complexes were added to a 2-ml cell suspension (1  ￿ 
106 cells/well,  6-well plate) in OM, incubated overnight at 37~ 
and then diluted with an equal  volume of OM-20% FCS.  Ex- 
pression of PfSSP2 by B-LCL transfected with pHbAnSSP2 was 
confirmed by immunofluorescence using a PfSSP2-specific  poly- 
clonal mouse serum  (15, 26).  Peptide-pulsed target  cells were 
prepared by overnight incubation of B-LCL with 15 tzM of indi- 
vidual synthetic peptides.  To determine minimal CTL epitopes, 
HLA-B8-Hmy2.C1R cells were pulsed with each peptide at the 
indicated concentrations. All target  cells were labeled overnight 
with 100 p,  Ci (1  Ci =  37  GBq) of a sterile Na2SlCrO4 solution 
(Dupont New England Nuclear, Boston, MA). 
SlCr-Release Assay.  Effector  cells were washed,  diluted with 
TCM,  and placed  into  triplicate  wells  of 96-well round-bot- 
tomed plates  (Costar  Corp.,  Cambridge, MA).  Triplicate wells 
were  also plated  with  effector  cells that  had been depleted of 
CD4 + or CD8 + T cells (>95%, by flow cytometric analysis). Im- 
mnnomagnetic depletion  was  performed  using anti-CD4-  or 
anti-CD8-coated immunobeads (Dynal, Inc., Great Neck, NY). 
Target  cells were  washed  three  times and resuspended at  5  ￿ 
104/ml in TCM, and 5 ￿  103 cells were added to wells contain- 
ing 100 I*1 effectors. Peptides  were included at 7.5  p~M in those 
wells containing  peptide-coated targets. Plates were centrifuged at 
500 g for 2 rain and incubated for 6 h at 37~  5% CO2. After in- 
cubation,  supernatants  were  harvested  (Skatron,  Inc.,  Sterling, 
VA), and released SlCr was counted in a gamma counter. Percent 
specific lysis was calculated from the following formula:  100 (ex- 
perimental release  -  spontaneous release)/(maximum release  - 
spontaneous release). Maximum and spontaneous release  were 
determined in wells containing  no effectors in the presence or ab- 
sence of 5% Triton X-100, respectively. Spontaneous release val- 
ues varied from 19-23% for transiently transfected targets and 11- 
20% for peptide-pulsed targets. 
Results 
Antigen-specific, Genetically Restricted, and  CD8  + T  Cell- 
dependent  CTL  Recognition  of  Endogenously  Synthesized 
PfSSP2.  To  determine whether the  immunization with 
P. falciparum irr spz induced PfSSP2-specific CTL,  frozen 
PBMC from both HLA-B8  + volunteers were in vitro stim- 
ulated with  autologous cells infected with  a  recombinant 
PfSSP2 vaccinia virus (vPl155) (26), and cytotoxic activity 
of effector cells was tested against HLA-matched and -mis- 
1437  Wizel et al. matched  target  cells transiently  transfected  with  a  plasmid 
DNA containing the entire 3D7 PfSSP2 gene (pHbAnSSP2). 
Effector cells from volunteers  16 and  17  expressed 62  and 
33% specifc  cytotoxic activity against matched cells trans- 
fected  with  pHbAnSSP2,  respectively  (E/T  ratio  80:1) 
(Fig.  1).  No significant lysis was detected  against the same 
matched  cells transfected  with  pHbAn  (no  insert)  or  mis- 
matched  lkH  target  cells  (Table  1)  transfected  with 
pHbAnSSP2  (Fig.  1). Upon depletion ofCD8 § T  cells, the 
lysis  against  autologous  target  cells  transfected  with 
pHbAnSSP2 was reduced by 80 and 78% for volunteers  16 
and 17, respectively (E/T ratio 80:1).  In contrast, the extent 
of CTL  activity remained  unchanged  when  the  CD4 +  T 
cell subset was depleted in both effector cell populations (E/ 
T  ratio  80:1)  (Fig.  1).  Using  the  same  recombinant  vac- 
cinia/transient  transfection  system,  effector  cells  obtained 
from frozen PBMC that were isolated from the same volun- 
teers before the initiation of the immunization were unable 
to  kill  similarly  prepared  target  cells  (data  not  shown). 
Thus,  naturally  processed  PfSSP2  presented  by stimulator 
and target cells provided an efficient system to demonstrate 
that  exposure  to  the  irr  spz  vaccine  induced  a  CTL  re- 
sponse  that was  PfSSP2  specific,  genetically restricted,  and 
largely dependent on CD8 + T  cells. 
CTL Responses  to PfSSP2-derived Peptides Bearing HLA- 
B8-binding Motif.  The  CD8 + T  cell-dependent  CTL re- 
sponse  observed  against  endogenously  generated  PfSSP2 
peptides could have been restricted by any of the HLA class 
I  alleles  expressed  on  the  target  cells  of each  volunteer. 
Therefore,  to identify regions of PfSSP2  containing HLA- 
B8-restricted  CTL  epitopes,  five PfSSP2-derived  15-mers 
(Table 2) bearing sequences conforming to the HLA-B8 al- 
A 
80" 
6O 
| 
20' 
Volunteer  16 
M~ch~I-pHbAnSSPZ 
Mim~tch~l-pltbAnSSP2 
80:1 40:1  20:1 -CD4 -CD8 
Effector/Target  ratio 
B Volunteer  17 
40" 
30-  ~ 
20- 
10 
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0  ~ 
-10  80:1 40:1  20:1 -CD4 -CD8 
Effector/Target  ratio 
Figure  1.  Genetically  restricted and CD8 + T  cell-dependent lysis of 
PfSSP-transfected cells by vP1155-stimulated PBMC.  Frozen PBMC 
from volunteers 16 (A) and 17 (B) obtained 2 and 3 wk after the last dose 
and after 583 and 652 cumulative bites from irradiated infected mosqui- 
toes, respectively, were  thawed and cocultured for 6 d with  vP1155- 
infected autologous cells at a 2 : 1 responder/stimulator ratio. After deple- 
tion ofCD4 + or CD8 + T cells, cytotoxicity of undepleted and depleted 
effector cell populations was measured against matched target cells (autol- 
ogous B-LCL) transfected with pHbAnSSP2 at indicated E/T ratios. De- 
pleted effector cells were tested at an E/T ratio of 80: 1. Cytotoxic activ- 
ity of undepleted effector cells was also measured against matched cells 
transfected with  pHbAn  and  mismatched  PC  cells transfected with 
pHbAnSSP2. Error bars represent SEM of triplicate assays. 
lele--specific binding motif (30-32)  were used  to stimulate 
PBMC  in in vitro bulk cultures.  After 6  d,  each  peptide- 
stimulated effector cell population was assayed for its ability 
to lyse autologous  target cells sensitized with  the homolo- 
gous peptide. 
PfSSP2 peptide-specific cytotoxic activity could be dem- 
onstrated in both HLA-B8 + volunteers.  The CTL activity 
was detected against two of the five peptides.  Effector cells 
obtained after stimulation with overlapping peptides 21  (IRL- 
HSDASKNKEKAL)  and  22  (DASKNKEKALIIIKS)  dis- 
played significant CTL activity (range of 23-28%, E/T ratio 
50 : 1) against autologous target cells pulsed with the homol- 
ogous peptide but not against autologous target cells pulsed 
with  PfSSP2  peptide  99  (Fig.  2).  Similar results were  ob- 
tained in two and three additional  assays from a total of six 
and eight experiments conducted for volunteers  16 and  17, 
respectively.  In  each  experiment  and  for  each  volunteer, 
stimulation  with  peptides  52  and  53  failed to generate  ef- 
fector cells with cytotoxic activity. Significant peptide-spe- 
cific  CTL  activity  (volunteer  16,  27.6%;  volunteer  17, 
23.9%;  E/T  ratio  50:1),  however,  was  detected  in  one 
experiment for PBMC  stimulated with peptide  7  (NIVD- 
EIKYREEVCND).  Additional  experiments  to  reproduce 
such  results  proved  unsuccessful.  These  data  indicate  that 
immunization  with  in" spz induces  a  PfSSP2  peptide--spe- 
cific CTL response in both HLA-B8 + individuals.  In addi- 
tion,  these  results  suggest  the  presence  of a  CTL  epitope 
within  the  10-amino  acid sequence  that is shared between 
peptides 21  and 22. 
HLA Restriction Analysis.  To determine the HLA class I 
restriction  element responsible for the presentation  of pep- 
tides 21  and 22,  CTL were generated from the two HLA- 
B8 § volunteers by culture of PBMC with each peptide and 
were tested for their ability to kill peptide-pulsed allogeneic 
B-LCL that partially shared  the  HLA class I  alleles present 
on effector cells.  In the first part of the analysis, we deter- 
mined  whether  peptide  21-  and  22-stimulated  PBMC 
from each volunteer were able to recognize  the respective 
peptide-pulsed  B-LCL  target  cells  from  both  volunteers. 
Target cells from volunteers  16 and 17 sensitized with pep- 
tides 21 and 22 were lysed by the respective peptide-stimu- 
lated effector cells from volunteer  16  (Fig.  3 A).  Similarly, 
peptide-pulsed target cells from volunteers  17 and  16 were 
recognized  equally  well  by  the  respective  peptide-stimu- 
lated effector cells from volunteer 17 (Fig. 3 B). Because, in 
addition  to the HLA-B8 allele, volunteers  16 and  17 share 
the  HLA-A1  and -Bw6 alleles  (Table  1),  it is possible that 
one, two, or all three class I alleles could have served as the 
restriction elements for the epitopes within peptides 21  and 
22.  However,  vP1155-stimulated  PBMC  were  unable  to 
kill  mismatched  HLA-AI-,  HLA-B8-,  HLA-Bw6 +  R.H 
cells  (Table  1)  transfected  with  the  PfSSP2  gene  (Fig.  1). 
The failure ofpeptide 21- and 22~specific CTL from both 
volunteers  to  recognize  peptide-pulsed  WB.  or  Gt<  cells 
indicates that the  class  I alleles HLA-A1  (shared by volun- 
teers 16 and 17 and WR  cells) (Fig. 3, A  and B), HLA-A24 
and HLA-Cw7  (shared by volunteer 16 and GP- cells) (Fig. 
3  A), and HLA-B7  (shared by volunteer  17 and GR  cells) 
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Figure  2.  Cytotoxic activity of PBMC stimulated in 
vitro with PfSSP2 peptides bearing the HLA-B8-bind- 
ing motif. Effector cells from volunteers 16 (A) and 17 
(B) that were obtained after a 6-d culture with the indi- 
cated pepticles (15 FLM) were tested against autologons 
B-LCL pulsed with the same peptides (symbols with con- 
tinuous lines) or with  negative control peptide 99  (15 
I-LM) (symbols with broken lines) in a 6-h SlCr-release assay 
at indicated E/T ratios. 
(Fig. 3 B) do not participate in the restricted presentation of 
these  epitope-bearing peptides.  These  results,  and the  fact 
that the stimulating peptides contain sequences conforming 
to the HLA-B8-binding motif (30-32), whose features dif- 
fer markedly from the motif~ described for alleles  HLA-A1 
(31),  HLA-A24 (43),  HLA-B7  (44),  and  HLA-Cw7  (45), 
demonstrate  that  the  CTL response  from both volunteers 
to PfSSP2 peptides 21 and 22 is HLA-B8 restricted. 
PfSSP2  Peptide-specific,  Genetically  Restricted  CTL  Activity 
Is Dependent  on  CD8 + T  Cells.  Peptide  22 not only con- 
tains  the  same  HLA-B8  motif-bearing  9-amino  acid  se- 
quence present in peptide  21, but also contains two addi- 
tional sequences with such a motif (Table 2). To determine 
if the  cytolytic  activity  was  dependent  on  CD8 §  CTL, 
PBMC from volunteers  16 and 17 were stimulated in vitro 
with  peptide  22,  and the  activity of the  effector cells  was 
studied  in  depletion  experiments.  Only  undepleted  and 
CD4 + T  cell-depleted  effector cell populations from both 
volunteers  recognized  autologous  target  cells  pulsed  with 
peptide  22  (Fig.  4).  The cytotoxic activity was dependent 
on CD8 § T  cells because the killing was eliminated by the 
depletion of this T  cell subset (Fig. 4). Autologous and WP,. 
target cells pulsed respectively with PfSSP2 peptides 99 and 
22 were not lysed by both undepleted effector cell popula- 
tions,  confirming the genetically restricted and specific na- 
ture of the CTL response (Fig. 4). 
Binding  to HLA-B8  and CTL  Recognition  of Predicted Mini- 
mal Epitopes.  Based  on  the  foregoing  results,  six  shorter 
peptide analogues representing the HLA-B8 motif-bearing 
sequences within  the  five 15-mers  (Table  2)  were synthe- 
sized to determine the ability of predicted epitopes to bind 
to HLA-B8 class I molecules in an in vitro assay that mea- 
sures the peptide-dependent incorporation of 12Sl-~2m into 
HLA complexes (39).  Peptides 22.1  (ASKNKEKAL), 22.2 
(KNKELALII), and  22.3  (KNKEKALI),  representing  the 
putative  CTL epitopes within peptides  21  and 22, formed 
stable  HLA  H  chain-~2m-peptide  heterotrimeric  com- 
plexes. The tl/2 for dissociation of 125I-~2m from complexes 
made with these shorter analogues was 0.5, 0.5 and 4 h, re- 
spectively (Table 3). Although CTL responses were not re- 
producibly detected for peptide 7, peptide 7.1 (EIKYREEV) 
bound detectably to HLA-B8 with a  tl/2 of 2 h  (Table  3). 
Similarly, the octamer 52.2 (RSR.KREIL) sequence, which 
maps  within  the  10-amino  acid  overlap  of negative  pep- 
tides 52 and 53, was shown to bind to HLA-B8 with a dis- 
sociation rate  of tl/2  =  1  h  (Table  3).  Only peptide  52.1 
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Figure 3.  Demonstration of HLA-B8-restricted cyto- 
toxic activity to PfSSP2 peptides 21 and 22. PBMC from 
volunteers 16 (A) and 17 (B) were cultured for 6 d with 
each peptide (15 I~M). Cytotoxic activity ofeffector cells 
was tested at the indicated E/T ratios against autologous 
and allogeneic HLA-B8-matched target cells pulsed with 
the respective stimulating peptides (15 I~M) (symbols with 
continuous lines). Peptide-pulsed (15 I~M) WR and GR 
cells (Table 1) were used as partially mismatched target 
cells (shared HLA class I alleles shown in parentheses) 
(symbols with broken lines). 
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CD8 + T cells. After 1,127 and 1,163 bites of irradiated infected mosqui- 
toes during 18 mo and 2 wk after the last exposure, PBMC from volun- 
teers 16 (A) and 17 (/3) were stimulated in vitro with peptide 22 (15 IxM). 
After 6 d of culture, effector cells were depleted of CD4  + or CD8 + T 
cells. Cytotoxic activity of depleted and undepleted effector cells was 
tested at an E/T ratio of60:1 in a 6-h SlCr-release assay against matched 
(autologous) and mismatched WR target cells pulsed with the same peptide 
(15 IxM). Autologous B-LCL pulsed with peptide 99 (15 p,M) were used 
as a negative control for peptide-specific lysis. 
(GTR.SRKR~I),  a  nonamer  within  peptide  52,  failed  to 
form complexes in the in vitro reconstitution  assay (Table 
3).  From this analysis, it can be concluded that the octamer 
and  two  nonamers  representing  the  putative  HLA-BS- 
restricted CTL epitopes within peptides 21 and 22 bind ef- 
fectively to HLA-B8. 
To  determine  whether  the  HLA-B8-binding  peptides 
within  overlapping peptides 21  and 22 represent  the mini- 
mal CTL-defined epitopes, PBMC from volunteer 17 were 
Table 3.  Peptide  Binding to HLA-B8 
Percentage of 
incorporation  tl/2 
Peptide  Sequence*  of 125I-~2m*  (h at 37~  w 
7.1  EIKYREEV  60  2 
22.1  ASKNKEKAL  50  0.5 
22.2  KNKEKALII  40  0.5 
22.3  KNKEKALI  50  4 
52.1  GTRSI<KREI  10  -- 
52.2  RSRKREIL  50  1 
NP 380-38811  ELP,.SRYWAI  50  3 
BCP, 1303-1311 ~  LTINKEDDE  7  -- 
No peptide  10  -- 
* Sequence in single-letter amino acid code. 
*Percentage of human ~2m incorporated into HLA-B8 complexes us- 
ing  HLA-B8 heavy chains, peptide,  and  12sI-f32m. HLA complexes 
were detected by gel filtration (39). Incorporation of 125I-~2m at levels 
>20% indicates specific binding. 
~Dissociation rate (tl/~) of 12sI-~2m from reconstituted complexes mea- 
sured at 37~  (38, 39). Values are accurate within a factor of two. 
IIPositive control peptide (30, 32) (with HLA-B8-binding motif). 
Negative control peptide (37) (without HLA-B8-binding motif). 
stimulated  in vitro  with  peptides  21  and  22  and were  as- 
sayed  for  their  ability  to  kill  HLA-B8-Hmy2.CIP,.  cells 
sensitized with  the  stimulating peptide  (15-mer)  and with 
the  shorter peptides  22.1  (9-mer),  22.2  (9-mer),  and 22.3 
(8-mer)  over a range of concentrations.  Peptide 21-stimu- 
lated PBMC recognized HLA-B8-Hmy2.C1R cells pulsed 
with  10  b~M of the  homologous peptide  (19%,  E/T  ratio 
60: 1) or with as little as 0.1  ~M ofpeptide 22.1  (23%, E/T 
ratio 60 : 1),  and they failed to recognize target cells  pulsed 
with peptides 22.2 or 22.3 at any of  the concentrations tested 
(Fig.  5  A).  Effector  cells  generated  by  stimulation  with 
peptide  22  recognized  equally  well  HLA-B8-Hmy2.C1R 
cells individually pulsed with  10  p,M of peptides  22,  22.1, 
22.2,  and 22.3  (range of 19-25%, E/T  ratio  60: 1).  While 
the  CTL  activity  against  target  cells  pulsed  with  each 
shorter peptide was not diminished by decreasing the puls- 
ing concentration to  1  p~M, the activity against target cells 
pulsed with peptide  22 was sharply reduced to the  cut-off 
value  considered as positive  (from 22  to  10.4%,  E/T  ratio 
60:1). At 0.1  }xM, only target cells  pulsed with each of the 
shorter  peptides  remained  susceptible  to  lysis  (Fig.  5  B). 
Control  target  cells  pulsed  with  no  peptide  or with  pep- 
tides representing the HLA-B8-restricted epitope of influ- 
enza NP 380-388 and the HLA-A2.1-restricted epitope of 
HBVc 18-27 were not lysed (Fig. 5, A  and B). These find- 
ings indicate that PfSSP2-derived peptides 21  and 22 con- 
tain at least two minimal HLA-B8-restricted CTL epitopes: 
the  nonamer  22.1  (ASKNKEKAL)  and  the  octamer  22.3 
(KNKEKALI),  a  truncated  form  of  the  nonamer  22.2 
(KNKEKALII). Because Hmy2.C1R cells  express only low 
levels  of HLA-B35 and  normal levels  of HLA-Cw4  (46), 
and none  of the volunteers  expressed  HLA-B35 or HLA- 
Cw4 (Table  1),  the lysis  of HLA-B8-Hmy2.C1P, transfec- 
tants  (31)  substantiates  the  conclusion  that  the  observed 
CTL responses are HLA-B8 restricted. 
Cytotoxic Activity  of Circulating  Activated  CTL.  PBMC  from 
volunteer 16 were isolated after 1,127 bites of irradiated in- 
fected  mosquitoes  (2  wk  after  the  last  exposure  to  145 
bites),  and an aliquot  of the  cells  was directly tested  at an 
E/T ratio of 100:1 for their ability to kill SlCr-labeled au- 
tologous B-LCL coated with  the  15-mers 21  and 22.  Sig- 
nificant CTL activity was detected against target cells  sensi- 
tized  with  peptide  21  (25.4%)  or peptide  22  (27.9%)  but 
not against target cells alone  (4.9%)  or pulsed with peptide 
99  (7.2%).  To  determine  the fine specificity of circulating 
activated  CTL,  a  similar  experiment  was  conducted using 
the same volunteer's PBMC obtained after 1,415 infectious 
bites (2 wk after the last  exposure to 122 bites)  and directly 
cultured with SlCr-labeled target cells  coated with peptides 
21  and  22  as  well  as  with  the  shorter  peptide  analogues, 
22.1, 22.2, and 22.3. At an E/T ratio of 100: 1, freshly iso- 
lated PBMC lysed autologous B-LCL pulsed with peptides 
21  (18.4%),  22  (19.6%),  and 22.1  (24.3%),  but did not lyse 
target  cells  pulsed  with  peptides  22.2  (1.9%)  and  22.3 
(5.7%). The lack of killing of target cells  pulsed with HLA- 
BS-restricted  NP 380-388  (2.6%)  and HLA-A2-restricted 
HBVc  18-27  (1.5%)  peptide  epitopes  indicated  that  the 
CTL activity is PfSSP2 specific. 
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Figure 5.  Fine  specificity of HLA-B8-restricted cyto- 
toxic response to PfSSP2 peptides 21 and 22. 2 wk after 
the last exposure, PBMC from volunteer 17 were ob- 
tained after having received 1,398 bites of irradiated in- 
fected mosquitoes over a period of 23 mo and were cul- 
tured for 6 d with peptides 21 (A) and 22 (B) (15 p~M). 
Generated effector  cells were tested for cytotoxic activity 
at an E/T  ratio of 50:1  against HLA-B8-Hmy2.C1R 
target cells pulsed with the indicated concentrations of 
stimulating 15-mer and  with  shorter HLA-B8 motif- 
bearing peptides 22.1, 22.2, and 22.3. Peptides NP 380- 
388 and HBc 18-27 were used as negative controls. 
Discussion 
These  studies  demonstrate  that  immunization  of HLA- 
B8 + volunteers with radiation-attenuated P. falciparum sporo- 
zoites  induces  antigen-specific,  CD8 +  T  cell-dependent, 
HLA-B8-restricted cytotoxic activity against a nine-amino 
acid (ASKNKEKAL) and an eight-amino acid (KNKEKALI) 
PfSSP2  peptide.  Furthermore,  circulating  activated  CTL 
against the ASKNKEKAL peptide were detected in the pe- 
ripheral blood of one of the two volunteers. 
Any vaccine designed to induce CD8 + CTL for the pre- 
vention or treatment of infectious diseases and malignancies 
must include protective or therapeutic  epitopes recognized 
by CTL from individuals of diverse HLA backgrounds. We 
consider PfSSP2 (15), also known as TRAP (16), as an im- 
portant target protein for malaria vaccine development, be- 
cause work in BALB/c (H-2  a) mice demonstrates that adop- 
tive transfer of CD8 + CTL against PySSP2 provides sterile 
immunity against  highly infectious  P.  yoelii  sporozoites  in 
the  absence  of other  parasite-derived  immune  responses 
(20). Furthermore, it has been shown that immunization of 
mice with recombinant mastocytoma cells expressing PySSP2 
induces  protective  immunity that is eliminated  by in vivo 
depletion ofCD8 + T  lymphocytes (47). We consider iden- 
tification  of HLA-B8-restricted  epitopes  as  an  important 
component of our overall strategy, because the HLA-B8 al- 
lele  is  expressed  in  Caucasian  (18.1%),  Black  (6.3%),  His- 
panic (9.0%), and Chinese (3.6%) populations (48). 
Our strategy for identifying class  I HLA-restricted CTL 
epitopes  recognized by PBMC  of volunteers with specific 
HLA  types  begins  with  the  assessment  of CTL  activity 
against endogenously produced epitopes in target cells tran- 
siently  transfected  with  the  full-length  PfSSP2  gene  (Fig. 
1).  Once a volunteer is determined  to be a responder,  we 
then  proceed to identify specific  epitopes.  Because  of the 
cost  and  time  required  for  synthesis  of peptides,  the  re- 
quirement  for  identifying  multiple  epitopes  restricted  by 
different class I HLA alleles,  and our interest in identifying 
B  cell and  class  II-restricted  epitopes,  we synthesized  113 
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overlapping 15-amino acid peptides representing the entire 
sequence of PfSSP2 to produce a set of reagents useful for 
numerous studies.  PBMC from volunteers immunized with 
P. falciparum  irr  spz are  then  studied  to  determine  if they 
have evidence of CTL against peptides that include sequences 
conforming to class  I  HLA-binding motifs  corresponding 
to the alleles  expressed by each individual.  We next deter- 
mine the ability of shorter peptides  to bind to the specific 
HLA molecule and  assess  their  capacity to sensitize  target 
cells in cytotoxicity assays. 
Five PfSSP2-derived 15-mers containing sequences con- 
forming to the HLA-B8 motif were selected for these stud- 
ies.  CTL responses were detected in both volunteers against 
two peptides,  21 and 22 (Fig. 2).  In each assay where pep- 
tide-specific CTL responses were detected,  activity was as- 
sociated with both peptides.  This finding suggested that the 
HLA-B8  motif-bearing  sequence  ASKNKEKAL  found 
within  the  10-amino  acid  overlap  of peptides  21  and  22 
could represent a CTL epitope. Additional evidence for the 
presence of an epitope within the overlapping sequence of 
both peptides was provided by an experiment demonstrat- 
ing  the  ability  of effectors  stimulated  with  peptide  21  to 
recognize and  kill  target  cells  pulsed  with peptide  22  and 
vice versa (Fig. 3). 
We  next  demonstrated  that  PBMC  from  each  of the 
volunteers  that  were  stimulated  in  vitro  with  peptide  21 
and 22 generated CTL activity that was restricted by HLA- 
B8 class 1 molecules (Fig. 3) and mediated by CD8 + T  cells 
(Fig.  4).  HLA-B8 restriction  was demonstrated using pep- 
tide-pulsed  allogeneic  B-LCL  sharing  class  I  HLA  alleles 
with  the  effector cells  of both  volunteers  (Fig.  3).  How- 
ever, in the case of volunteer 17, restriction analysis did not 
include  B-LCL  target  cells  sharing  the  HLA-A3  allele. 
Since PfSSP2 peptide 21 contains a 10-amino acid segment 
that conforms to the HLA-A3-binding motif (49)  (RLHS- 
DASKNK)  (Table  2),  it  is  therefore  theoretically possible 
that,  in addition  to the presence  of an HLA-B8-restricted CTL epitope, peptide 21  could contain a determinant re- 
stricted by the A3 allele. 
It is possible that, by studying 15-mers instead of a direct 
analysis  of motif-bearing  8-10-amino  acid  peptides,  we 
may have missed the presence of CTL responses against se- 
quences within peptides 7, 52, and 53. The longer peptides 
may have inherent resistance or increased susceptibility to 
extracellular serum proteases (50,  51), which could lead to 
minimal or extensive processing of the longer peptides and, 
therefore, to a failure to  adequately stimulate  effectors or 
sensitize targets.  We therefore synthesized the six eight to 
nine-amino  acid  peptides  within  peptides  7,  21,  22,  52, 
and 53 that conform to the HLA-B8-binding motif. Five 
of the six bind to HLA-B8 (Table 3).  However, peptides 
7.1  and 52.2 (Table 2), both of which were shown to bind 
to HLA-B8 (Table 3), were unable to generate effectors or 
sensitize  targets  for  cytolytic  activity  (data  not  shown). 
Thus, there is no evidence that use of the 15-mers was as- 
sociated with  decreased  sensitivity in  detecting  CTL  re- 
sponses. 
The short peptides were then used to map the minimal 
CTL  epitopes  within  peptides  21  and  22.  These  studies 
clearly demonstrate the  presence of at least two  PfSSP2- 
derived peptides that bind to HLA-B8 and are recognized 
by CD8 + human  CTL: a nonamer, ASKNKEKAL (pep- 
tide 22.1), and an octamer, KNKEKALI (peptide 22.3). In- 
asmuch as  the  nonamer KNKEKALII  (peptide 22.2)  also 
sensitized  HLA-B8-Hmy2.CIk cells  for lysis  by peptide 
22-stimulated  effector cells  at  levels comparable to  those 
obtained for target cells pulsed with peptide 22.3, it is pos- 
sible  that this peptide represents a distinct epitope.  How- 
ever, it is likely that the ability of both peptides to be simi- 
larly  recognized  by  CTL  is  a  result  of the  extracellular 
processing ofpeptide 22.2 by serum peptidases (50, 51) that 
remove the  COOH-terminal  Ile,  thereby generating the 
octamer represented in peptide 22.3.  Moreover, although 
high-affinity peptide ligands can have values of tl/2 for dis- 
sociation at 37~  as short as 0.5 h (52), peptide 22.3 bound 
to  HLA-B8  molecules  with  an  eightfold  higher  affinity 
than peptide 22.2  (Table 3).  We thus favor peptides 22.1 
and 22.3 as the minimal HLA-B8-restricted epitopes. 
Because we did not synthesize and test truncated peptides 
from the sequences of 22.1  and 22.3,  it could be argued 
that they do not represent the minimal CTL epitopes. Se- 
quence information from endogenous HLA-B8-associated 
peptides have revealed that, although the majority of pep- 
tides were of eight or nine amino acids  in length, a small 
proportion of naturally occurring peptides yielded sequences 
of seven amino acids (31). Thus, the sequence KNKEKAL, 
which  is  present within  peptides  21,  22,  22.1,  22.2,  and 
22.3  (Table 2),  could theoretically represent the  minimal 
epitope. However, this is unlikely because peptide 21-stim- 
ulated effector cells lysed HLA-B8-Hmy2.C1P,. cells pulsed 
with peptide 22.1, but not the same cells pulsed with pep- 
tide 22.2 or 22.3 (Fig. 5 A). 
Besides  MHC  polymorphism,  antigen  variation  repre- 
sents  an  additional  obstacle  to  development  of peptide- 
based vaccines. Indeed, analysis of  the natural sequence vail- 
ation of the PfSSP2/TRAP gene revealed that this antigen 
is highly polymorphic (53).  However, it is of considerable 
importance that, from the sequence data on 14 P. falciparum 
isolates,  all the residues within the nonamer peptide ASK- 
NKEKAL are conserved. In contrast, the COOH-terminal 
lie 116 in the octamer peptide KNKEKALI has been shown 
to vary. This variation is limited, since the replacement of 
Ile for Set at such position is present in only 1 of the  14 
published sequences (53). Whether the substitution of this 
auxiliary anchor residue will interfere with the binding of 
such peptide to HLA-B8 and thereby abrogate the CTL re- 
sponse  remains  to  be  determined.  Because  the  nonamer 
peptide ASKNKEKAL is a target of CTL in HLA-B8 indi- 
viduals  and  is  conserved among various P. falciparum  iso- 
lates,  it may become an  important component of malaria 
vaccines designed  to  attack  infected hepatocytes.  Further 
work must be carried out to confirm that this  sequence is 
conserved and to establish that CTL against this peptide rec- 
ognize and eliminate parasitized hepatocytes in vivo. 
Thus  far,  HLA-B8-restricted CTL epitopes  have  been 
identified in the influenza A virus nucleoprotein (30,  32), 
EBV nuclear antigen 3 (54),  HIV-1  gp41  (55),  HIV-1 pol 
protein (56),  and the HIV-1  gag protein (30,  55,  57,  58). 
All these epitopes are eight or nine amino acids long. This 
is  the  first  report identifying HLA-B8-restricted epitopes 
for an antigen of nonviral origin. 
Although the selection of PfSSP2-derived peptides with 
sequences conforming to the HLA-B8-binding motif  proved 
useful as a strategy for the eventual identification of CTL 
epitopes (ASKNKEKAL and KNKEKALI), it is clear from 
our analysis that the presence of primary and auxiliary an- 
chor  residues  is  not  sufficient  for  binding  to  HLA-B8 
(GTRSRKREI), and that the ability of motif-bearing pep- 
tides to bind HLA-B8 molecules in the reconstitution assay 
(EIKYREEV  and  R.SRKREIL)  does  not  guarantee  that 
the peptides will be biologically relevant. Therefore, substi- 
tution  analysis  using  a  large  panel  of synthetic analogues 
may be required to refine the HLA-B8-binding motif by 
defining the  contribution of residues  other than  those  at 
positions 3 and 5 and the COOH terminus in the binding 
capacity of peptide ligands  to HLA-B8 molecules. Such an 
analysis has been successfully  conducted for the HLA-A2.1 
allele,  for which  the  binding motif has  been adjusted  by 
identifying the  nonanchor residues that favor or interfere 
with binding to A2.1 molecules (59). 
During the course of this study, the two HLA-B8  + vol- 
unteers were found to be protected against malaria after ex- 
posure to the bites of five nonirradiated mosquitoes carry- 
ing  P. falciparum  sporozoites in  their salivary  glands.  The 
challenge was conducted after 1,127 (volunteer 16) and 1,163 
(volunteer 17) bites of irradiated infected mosquitoes over a 
period of 18 mo and 2 wk after the last exposure. We be- 
lieve  that  the  protection is  primarily mediated by CTL- 
recognizing peptides  from  PfSSP2  and  other  preerythro- 
cytic-stage antigens in the context of HLA class I molecules 
on  the  surface  of infected  hepatocytes.  The  HLA-B8- 
restricted and PfSSP2-specific CTL we identified may have 
contributed to this sterile protective immunity.  Nonethe- 
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strated in PBMC after in vitro restimulation is indicative of 
CTL activity in the liver. However,  the demonstration of 
circulating activated CTL against peptide 22.1  in volunteer 
16 suggests that the CTL we are detecting may be able to 
traffic to the liver and  eliminate infected hepatocytes. We 
have  demonstrated  similar activity against HLA-A*0201- 
restricted PfSSP2  CTL  epitopes  (60).  This  appears  to  be 
the first published evidence identifying circulating activated 
CTL against a nonviral antigen. 
Genetic restriction ofT  cell responses and polymorphism 
of target epitopes pose enormous problems for development 
of malaria vaccines designed to induce protective CTL re- 
sponses. The identification of a conserved HLA-B8-restricted 
CTL  epitope on  PfSSP2  constitutes  a  component  of our 
comprehensive strategy to develop peptide-based vaccines 
that will include multiple, conserved P. falciparum preeryth- 
rocytic-stage determinants restricted by class I  HLA alleles 
that  are  expressed at  moderate  to  high  frequency  among 
different ethnic  groups.  Work is now  in progress  to  map 
CTL  epitopes on  PfSSP2  that are restricted by a  range of 
HLA alleles and to carry out the same studies for other P. 
falciparum  proteins (25,  61-64)  expressed in infected hepa- 
tocytes. 
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